Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vacc

Reuters2021-05-20

Merck & Co Inc :Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vaccine.Merck & Co Inc - V114 Met Primary Immunogenicity And Safety Endpoints In Both Trials.Merck & Co Inc - V114 Was Generally Well-Tolerated, With A Safety Profile Comparable To Pcv13.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Aiduoduo
2021-05-20
Aiduoduo
Above 80$

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2136929079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-20 18:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2136929079","market":"us","top_or_hot":-1,"title":"Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vacc","media":"Reuters","content":"<html><body><p>Merck &amp; Co Inc <mrk.n>:Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vaccine.Merck &amp; Co Inc - V114 Met Primary Immunogenicity And Safety Endpoints In Both Trials.Merck &amp; Co Inc - V114 Was Generally Well-Tolerated, With A Safety Profile Comparable To Pcv13.</mrk.n></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vacc</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vacc\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-20 18:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.trkd.thomsonreuters.com><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck & Co Inc :Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal ...</p>\n\n<a href=\"https://www.trkd.thomsonreuters.com\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://www.trkd.thomsonreuters.com","article_id":"2136929079","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2136929079","pubTimestamp":1621507926,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"Merck & Co Inc :Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Pla","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"默沙东宣布针对默沙东15价肺炎球菌结合物V114的Pneu-Direction(V114-027)和Pneu-Plan(V114-024)3期儿科研究的阳性背线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"Merck & Co Inc :Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vaccine.Merck & Co Inc - V114 Met Primary Immunogenicity And Safety Endpoints In Both Trials.Merck & Co Inc - V114 Was Generally Well-Tolerated, With A Safety Profile Comparable To Pcv13.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":130973187,"gmtCreate":1621508646949,"gmtModify":1704358760455,"author":{"id":"3565395120709568","authorId":"3565395120709568","authorIdStr":"3565395120709568","name":"Aiduoduo","avatar":"https://static.tigerbbs.com/f5f80e003aa9dfbc1538b8fec369b2ff","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3565395120709568"},"htmlText":"Above 80$","listText":"Above 80$","text":"Above 80$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130973187","repostId":2136929079,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2136929079"}